Progressive Pulmonary Fibrosis (PPF) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2022 To 2032

Progressive Pulmonary Fibrosis (PPF) Market Outlook

Thelansis’s “Progressive Pulmonary Fibrosis (PPF) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2022 To 2032" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Progressive Pulmonary Fibrosis treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

Progressive Pulmonary Fibrosis (PPF) Overview

Progressive pulmonary fibrosis (PPF) is a lung disease that gets worse over time. It is caused by scarring of the lungs, which makes it harder to breathe. PPF can occur in people with any interstitial lung disease (ILD). However, it is more common in people with certain types of ILD, such as idiopathic non-specific interstitial pneumonia (iNSIP), connective tissue disease-related ILD (CTD-ILD), and fibrotic hypersensitivity pneumonitis. PPF is more likely to occur in older people who have smoked cigarettes, have bronchiectasis (widening of the airways), have a certain pattern of scarring on their lungs on a high-resolution computed tomography (HRCT) scan, have not had their disease improve, or stabilize, have short telomere syndrome, are Black American, or have gastroesophageal reflux disease (GERD). Certain biomarkers can be measured in the blood to help identify people who are at risk of developing PPF. These biomarkers include the MUCB promoter gene, KL-6, CCL-16, matrix metalloproteinases (MMP1, MMP7, MMP12), periostin, and tissue inhibitors of metalloproteinases (TIMP).

• PPF is more common in Europe and the United States than in other parts of the world. In Europe, the prevalence of PPF is 2.2-20.0 people per 100,000 people. In the United States, the prevalence of PPF is 28.0 people per 100,000 people.

Geography Covered:

North America- the United States and Canada

Europe- EU5 (Germany, France, Italy, Spain, and the United Kingdom)

Other countries- Japan & China

Study Period: 2022-2032

Current Clinical Practice and Treatment Algorithm

This section of the study covers country-specific current clinical practice, the standard of care, and significant limitations around addressing the unmet needs. Retrospective analysis and bench-marking of clinical study outcomes are presented in terms of Pre-treatment & post-treatment clinical and demographic patient characteristics. Essentially, this section will cover the evolution of the current competitive landscape and its impact on the future treatment paradigm.

KOL Insights:

KOLs across 8 MM markets from the center of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs

Market Forecast: Patient Based Forecast Model (MS. Excel Based Automated Dashboard)

- Data Inputs with sourcing

- Market Event and Product Event

- Country-specific Forecast Model

- Market uptake and patient share uptake

- Attribute Analysis

- Analog Analysis

- Disease burden and pricing scenario

- Summary and Insights

NPV/ IRR Calculator-

Optimization of cash flow/ revenue flow concerning all fixed and variable investments throughout the product development process. The rate of return on an investment is a critical indicator to ensure the profitability and break-even of the project.

Competitive Landscape:

The competitive landscape includes country-specific approved as well as pipeline therapies. Any asset/product-specific designation or review such as Orphan drug designation, Fast track, Priority Review, Breakthrough Therapy Designation, Rare Pediatric Disease Designation, and Accelerated Approval are tracked and supplemented with analyst commentary.

Clinical Trial Assessment-

Detailed clinical trial data analysis and critical product positioning include trial design, primary outcomes, secondary outcomes, dosing and schedules, inclusion and exclusion criteria, recruitment status and essentially covers the reported adverse events. Majorly the trial analysis helps determine the potential of the critical assets and their probable filing and launch date.

Unmet Medical Needs Overview-

This report presents the most important clinical unmet needs in the treatment, according to Thelansis research and analysis. Other essential unmet needs identified through our study include decreased cost burden on patients, improved administration convenience, and improved patient compliance.

Visit our social media pages: